Article Type
Case Report
Published
In this article authors review recent studies and evaluate the benefits and risks of combination therapy with an angiotensin converting enzyme (ACE) inhibitor and angiotensin II receptor blocker (ARB), or a direct renin inhibitor (DRI) to attenuate the progression of diabetic nephropathy.